News
Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...
Novo Nordisk continues to deliver double-digit revenue and profit growth, driven by both its diabetes and obesity drug ...
Novo Nordisk has been losing big in the past year and is down over 66% from its peak in 2024. On the other hand, Eli Lilly ...
Orforglipron led to 12.4% weight loss after 72 weeks while Novo Nordisk’s oral therapy showed a 13.6% drop in weight.
Otte took on the title in February, the culmination of nearly 25 years spent with the Danish drugmaker. As of his departure ...
Novo Nordisk CFO Karsten Munk Knudsen tells Yahoo Finance the company understands the pressure it is under to deliver better ...
The pharmaceutical company's quarterly sales of its blockbuster Wegovy drug surged by two-thirds, despite many Americans ...
Sales of Wegovy, launched locally in June, more than doubled to 5,000 units or 70 million rupees ($798,230) in July, the data ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback